Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits

Infection and Immunity

Volumn 65, Issue 6, 1997, Pages 2019-2028

  Bast, Darrin J ^a,d   Brunton, James L ^a,b,d   Karmali, Mohamed A ^c,d   Richardson, Susan E ^c,d,e  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; GLOBOTRIAOSYLCERAMIDE; VEROTOXIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BLOOD TOXICITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HEMOLYTIC UREMIC SYNDROME; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RIBOSOME SUBUNIT; TARGET CELL; TISSUE DISTRIBUTION;

EID: 0030922203     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.6.2019-2028.1997     Document Type: Article

References (36)

1. Bast, D. Unpublished data.
2. 1a.Bast, D. J., et al. Unpublished data.
3. 1b.Bielaszewska, M., M. A. Karmali, and M. Petric. 1994. Localization of verocytotoxin (VT2) and antigenic cross-reactivity of VT1 and VT2 in the rabbit model, p. 249-252. In M. A. Karmali and A. G. Goglio (ed.), Recent advances in Verocytotoxin-producing Escherichia coli infections. Elsevier Biomedical Press, Amsterdam, The Netherlands.
4. Clarke, C., D. J. Bast, A. Sharp, P. M. St. Hilaire, R. Agha, P. E. Stein, E. J. Toone, R. J. Read, and J. L. Brunton. 1995. Phenylalanine 30 plays an important role in receptor binding of verotoxin-1. Mol. Microbiol. 19:891- 899.
5. Endo, Y., K. Tsurgi, T. Yutsudo, Y. Takeda, T. Ogasawara, and K. Igarashi. 1988. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. Eur. J. Biochem. 171:45-50.
6. Frazer, M., M. Chernai, Y. Kozlov, and M. James. 1994. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 Å resolution. Nat. Struct. Biol. 1:59-64.
7. 4a.Glantz, S. A. 1992. Primer of biostatistics, 3rd ed. McGraw-Hill, Inc., New York, N.Y.
8. Head, S. C., M. A. Karmali, and C. A. Lingwood. 1991. Preparation of VT1 and VT2 hybrid toxins form their purified dissociated subunits. Evidence for B subunit modulation of A subunit function. J. Biol. Chem. 266:3617-3621.
9. Head, S. C., M. A. Karmali, M. E. Roscoe, M. Petric, N. A. Strockbine, and I. K. Wachsmuth. 1988. Serological differences between verocytotoxin 2 and Shiga-like toxin II. Lancet ii:751.
10. Hertzke, D., L. Cowan, P. Schoning, and B. Fenwick. 1995. Glomerular ultrastructural lesions of idiopathic cutaneous and renal glomerular vasculopathy of greyhounds. Vet. Pathol. 32:451-459.
11. Hofmann, S. L. 1993. Southwestern International Medicine Conference. Shiga-like toxins in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Am. J. Med. Sci. 306:398-406.
12. Karmali, M. A., M. Petric, C. Lim, R. Cheung, und G. Arbus. 1985. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151:775-782.
13. Kiarash, A., B. Boyd, and C. Lingwood. 1994. Glycosphingolipid receptor function is modified by fatty acid content. Verotoxin 1 and Verotoxin 2e preferentially recognize different globotriaosyl ceramide fatty acid homologues. J. Biol. Chem. 269:11138-11146.
14. Lingwood, C., H. Law, S. Richardson, M. Petric, J. L. Brunton, S. DeGrandis, and M. A. Karmali. 1987. Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J. Biol. Chem. 262:8834- 8839.
15. Louise, C. B., and T. G. Ogrig. 1991. Shiga toxin-associated hemolytic- uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1β, and tumor necrosis factor alpha on human vascular endothelial cells in vitro. Infect. Immun. 59:4173-4174.
16. MacLeod, D. L., and C. L. Gyles. 1991. Immunization of pigs with purified Shiga-like toxin II variant toxoid. Vet. Microbiol. 29:309-318.
17. O'Brien, A. D., V. Tesh, A. Donohue-Rolfe, M. Jackson, S. Olsnes, K. Sandvig, A. Lindberg, and G. T. Keusch. 1992. Shiga toxin: biochemistry, genetics, and mode of action and role in pathogenesis. Curr. Top. Microbiol. Immunol. 180:65-94.
18. Olsnes, S., R. Reisbig, and K. Eiklid. 1981. Subunit structure of Shigella cytotoxin. J. Biol. Chem. 256:8732-8738.
19. Pellizzari, A., H. Pang, and C. Lingwood. 1992. Binding of verocytotoxin 1 to its receptor is influenced by differences in receptor fatty acid content. Biochemistry 31:1363-1370.
20. Petric, M., M. A. Karmali, S. E. Richardson, and R. Cheung. 1987. Purification and biological properties of Escherichia coli verocytoxin. FEMS Microbiol. Lett. 41:63-68.
21. Ramegowda, B., and V. L. Tesh. 1996. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect. Immun. 64:1173-1180.
22. Ramotar, K., B. Boyd, G. Tyrrell, J. Gariepy, C. Lingwood, and J. L. Brunton. 1990. Characterization of Shiga-like toxin 1B purified from overproducing clones of the SLT-1 B cistron. Biochem. J. 272:805-811.
23. Richardson, S., T. Rotman, V. Jay, C. Smith, L. Becker, M. Petric, N. Olivieri, and M. Karmali. 1992. Experimental verocytotoxemia in rabbits. Infect. Immun. 60:4154-4167.
24. Richardson, S. E., M. A. Karmali, L. E. Becker, and C. R. Smith. 1988. The histopathology of the hemolytic uremic syndrome (HUS) associated with verocytotoxin-producing Escherichia coli (VTEC) infections. Hum. Pathol. 19:1102-1108.
25. Riley, L., R. Remis, S. Helgerson, H. McGee, J. Wells, B. Davis, R. Herbert, E. Olcott, L. Johnson, N. Hagrett, P. Blake, and M. Cohen. 1983. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308:681-685.
26. Sandvig, K. M. Ryd, O. Garred, E. Schweda, P. K. Holm, and B. van Deurs. 1994. Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the non-toxic Shiga-B-fragment is regulated by butyric acid and cAMP. J. Cell Biol. 126:53-64.
27. Sjogren, R., R. Neill, D. Rachmilewitz, and D. Fritz. 1994. Role of Shiga-like toxin I in bacterial enteritis: comparison between isogenic strains induced in rabbits. Gastroenterology 106:306-317.
28. Stein, P. E., A. Boodhoo, G. J. Tyrrell, J. L. Brunton, and R. J. Read. 1992. Crystal structure of the cell binding B oligomer of verotoxin-1 from Esche richia coli. Nature (London) 355:748-750.
29. Tesh, V. L., B. Ramegowda, and J. E. Samuel. 1994. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect. Immun. 62:5085-5094.
30. Tesh, V. L., and A. D. O'Brien. 1991. The pathogenic mechanisms of Shiga- toxin and the Shiga-like toxin. Mol. Microbiol. 5:1817-1822.
31. Tesh, V. L., J. E. Samuel, L. P. Perera, J. B. Sharefkin, and A. D. O'Brien. 1991. Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J. Infect. Dis. 164:344- 352.
32. Tyrrell, G. J., K. Ramotar, B. Toye, B. Boyd, C. A. Lingwood, and J. L. Brunton. 1992. Alteration of the carbohydrate binding specificity of vero- toxins from Galα1-4Gal to GalNAcβ1-3Galα1-4Gal and vice versa by site- directed mutagenesis of the binding subunit. Proc. Natl. Acad. Sci. USA 89:524-528.
33. Van der Kar, N. C. A. J., L. A. H. Monnens, M. A. Karmali, and V. W. M. van Hinsbergh. 1992. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogencsis of the hemolytic uremic syndrome. Blood 80:2755-2764.
34. Waddell, T., S. Head, M. Petric, A. Cohen, and C. A. Lingwood. 1988. Globotriaosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. Biochem. Biophys. Res. Commun. 152:674-679.
35. Wadolkowski, E. A., J. A. Burris, and A. D. O'Brien. 1990. Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7 Infect. Immun. 58:2438-2445.
36. Zoja, C., D. Corna, C. Farina, G. Sacchi, C. Lingwood, M. Doyle, V. V. Padhye, M. Abbate, and G. Remmuzzi. 1992. Tissue localization of verotoxin glycolipid receptor determines clinical expression of the disease in rabbits challenged with verotoxin-1. J. Lab. Clin. Med. 120:229-238.